Phase I study of TrasGEX, a glyco-optimised anti-HER2 monoclonal antibody, in patients with HER2-positive solid tumours
Walter Fiedler, Herbert Stoeger, Antonella Perotti, Guenther Gastl, Jens Weidmann, Bruno Dietrich, Hans Baumeister, Antje Danielczyk, Steffen Goletz, Marc Salzberg, Sara De Dosso
ESMO Open Jun 2018, 3 (4) e000381; DOI: 10.1136/esmoopen-2018-000381
